Leadership Team

Dr. Camillo Ricordi is Founder and President of AION Healthspan, Inc. After training at the University of Milan, Italy, at Washington University in St. Louis and at the University of Pittsburgh, since 1993 he has been working at the University of Miami Miller School of Medicine, where he is currently Professor of Surgery, Director of the Cell Transplant Center and Director Emeritus of the Diabetes Research Institute. Internationally recognized as a pioneer in cell therapies and regenerative medicine, he is well known for developing the technology for large-scale isolation of human pancreatic islets and for performing the first successful clinical islet allotransplants to reverse diabetes. He also led the first FDA-approved clinical trial using Mesenchymal Stromal Cell infusions to treat severe COVID-19.   His inventions resulted in 28 patents and over 100 honors and awards, including being Knighted by the President of Italy, the ADA Outstanding Scientific Achievement Award, and the induction in the National Academy of Inventors, for contributing outstanding inventions that have made a tangible impact on quality of life, economic development, and welfare of society. During over 40+ year academic career, he has authored more than 1,200 publications with over 60,000 citations (H-Index 117), including the Oscar Bestseller, The Healthspan Code (2022) and Therapeutic Revolution (2025).

Dr. Giacomo Lanzoni is Co-Founder and Chief Scientific Officer at AION Healthspan, Inc. He also serves as an Assistant Professor at the Diabetes Research Institute and the Department of Biochemistry and Molecular Biology at the University of Miami, focusing on translational research for Type 1 Diabetes. Dr. Lanzoni is the key co-inventor, alongside Dr. Camillo Ricordi, of a portfolio of patents and technologies in immunomodulation, stem cell therapy, and nanotherapeutics, licensed by AION Healthspan. He co-led with Dr. Ricordi a first-in-human clinical trial using Umbilical Cord–derived Mesenchymal Stem Cells (UC-MSCs) to treat severe COVID-19, demonstrating strong anti-inflammatory effects and strikingly improved patient outcomes. He holds a PhD in Stem Cell Biotechnology from the University of Bologna and has over 17 years of experience in the field. At AION Healthspan, Dr. Lanzoni is dedicated to translating science into scalable therapies that extend healthspan and improve lives.

Peter Molloy serves as Chief Operations Officer at AION Healthspan. Peter has over 25 years of experience creating, advising, and investing in healthcare‑focused private and public companies. Until 2021, he was Founder and CEO of Edison Group, building it into a global advisory and equity research firm with more than 100 staff and 500 corporate clients. He previously led biotech investing in London during the 1990s at Hermes Investment Management, overseeing healthcare and technology portfolios and championing shareholder activism. Mr. Molloy also co‑founded Tarus Therapeutics, an immuno‑oncology venture acquired by a Nasdaq‑listed biotech in 2022. Currently, he also serves as CEO of Cyncado Therapeutics, an immuno‑oncology biotech targeting the adenosine pathway. He earned his Economics degree from the University of Exeter, is an alumnus of London Business School, and holds the CFA (UK).

Bill Ford is the Chairman and a Founding Investor at AION Healthspan. He is currently the Chairman and Chief Executive Officer of General Atlantic, a leading global growth investor with approximately $100 billion under management across 20 countries. He joined the firm in 1991, became CEO in 2007, and was appointed Chairman in 2021. He has spent three decades supporting innovation and global collaboration, helping to broaden General Atlantic’s investment platform beyond Growth Equity into Credit, Climate, and Sustainable Infrastructure strategies. Mr. Ford serves on the boards of BlackRock and ByteDance, and previously held directorships at Sierra Space, First Republic Bank, NYSE Euronext, E*Trade, Priceline, and NYMEX Holdings. He is actively involved with The Rockefeller University as Chairman of its board of trustees, and also supports Memorial Sloan Kettering Cancer Center, the Council on Foreign Relations, Tsinghua University, and the National Committee on US-China Relations.

Bernard “Bernie” Siegel is a non-executive and founding investor at AION Healthspan. He is an attorney and patient advocate, widely recognized for forging a visionary movement that became the cornerstone of a legal framework advancing stem cell and regenerative medicine worldwide. Bernie founded the Genetics Policy Institute (now the Regenerative Medicine Foundation) and conceptualized and managed 20 annual global events—the World Stem Cell Summit—which served as a catalyst for valuable collaborations involving patients, researchers, industry leaders, and policymakers. In 2022, he co-founded the Healthspan Action Coalition, representing more than 250 cross-sector organizations promoting health longevity as a fundamental human right. A frequent speaker at major conferences and in media outlets worldwide, Bernie holds BA and JD degrees from the University of Miami and is a 50-year member of the Florida Bar.

Paolo Pucci serves as a non-executive director of AION Healthspan. Paolo is an accomplished pharmaceutical and biotech executive with a track record of advancing innovative oncology and targeted therapeutics. From 2008 until its acquisition by Merck in 2020, he served as Chief Executive Officer of ArQule, where he led the company’s growth and development of novel precision medicines. Previously, he spent seven years at Bayer AG in leadership roles that included President of the Oncology & Global Specialty Medicines Business Units. Mr. Pucci began his career at Eli Lilly and Company, serving as Managing Director of Eli Lilly Sweden AB. He holds an MS in Economics and Accounting from the Università degli Studi di Napoli Federico II and an MBA in Marketing and Finance from the University of Chicago. He currently sits on the boards of West Pharmaceutical Services Inc., Replimune Group Inc., and Merus N.V..